VR Logo

Inhibrx Inc. (INBX) download report


Healthcare | Biotechnology & Pharma Research

Inhibrx Inc. (INBX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates.

IPO Date: 19-Aug-2020

Founder, Chairman, Pres & CEO: Mr. Mark Paul Lappe

Founder & Chief Scientific Officer: Dr. Brendan P. Eckelman Ph.D.

Listing: NASDAQ: INBX

Country: United States

Headquarters: La Jolla, CA

Website: https://inhibrx.com

Key Facts

Market cap: $468.06 Mln

Revenue (TTM): $7.18 Mln

Earnings (TTM): $-93.73 Mln

Cash: $143.47 Mln

Total Debt: $115.45 Mln

Insider's Holding: 31.57%

Liquidity: Low

52 Week range: $7.67 - 47.90

Shares outstanding: 39,037,300

6 Years Aggregate:

  • CFO: $-220.32 Mln
  • EBITDA: $-234.06 Mln
  • Net Profit: $-259.90 Mln

Stock Performance

Time Period Inhibrx (INBX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-74.01-9.18-19.53
1 month-16.85-4.78-9.69
3 months-52.53-9.66-16.90
1 Year-57.620.81-17.67
3 Years--10.335.77
5 Years--11.345.69
10 Years--11.749.74
As on 30-Jun-2022 *As on 01-Jul-2022
Year Inhibrx (INBX) S&P Small-Cap 600 S&P BSE Sensex
202132.4525.2721.99